Further to the company’s announcement on the Saudi Stock Exchange’s website (Tadawul) on 3/5/1438 – 31/1/2017, concerning the transition plan towards the International Accounting Standards for the third phase; in addition to the company’s announcement published on the Saudi Stock Exchange’s website (Tadawul) on 27 /6/1438 – 26/3/2017 regarding the approval of the 8th Extraordinary General Assembly to the amendment of the company’s statute, which stated the conversion of the company’s fiscal year from the Hijri calendar year, which ends on 15/7/1438, to the Gregorian calendar year, which ends on 31/12/ 2017, Jabal Omar Development Company (JODC) announces its intention to amend its fiscal year from the Hijri calendar year, which ends on (30/12) to the Gregorian calendar year, which ends on (31/12), and that is by making an integrated plan to implement this transition; as the company will issue financial statements for the coming period, as follows:
- The company will issue the short Hijri fiscal year for 1438, which starts from 1/1/1438 and ends on 15/7/1438, and will be published during the statutory publication period using the Saudi accounting standards.
- The International Accounting Standards will apply starting from 13/4/2017.
- The company will issue the second Gregorian fiscal quarter for the year 2017, starting from 13/4/2017 till 30/6/2017 and will be published during the statutory publication period.
- The company will issue the third Gregorian fiscal quarter for the year 2017 for the three months (7/8/9) and will be published during the statutory publication period.
- The company will issue the fourth Gregorian fiscal quarter for the year 2017 for the three months (10/11/12) and will be published during the statutory publication period.
- The company will issue the short (Gregorian) fiscal year for 2017, which starts from 13/4/2017 and ends on 31/12/2017, and will be published during the statutory publication period. Furthermore, the company wishes to clarify that implementing this transition will not result in any adverse effects.